Literature DB >> 2449306

Serum levels of interferons in patients with systemic lupus erythematosus.

T Kim1, Y Kanayama, N Negoro, M Okamura, T Takeda, T Inoue.   

Abstract

Serum levels of alpha (alpha) and gamma (gamma)-interferons (IFN) were measured in 30 patients with untreated systemic lupus erythematosus (SLE) with a solid-phase, sandwich immunoradiometric assay using specific monoclonal antibodies. The serum levels of alpha-IFN were higher in patients with SLE than in normal subjects, and correlated with the clinical activity index (rs = 0.60, P less than 0.01), but not with renal histological activity. The serum level of alpha-IFN correlated with the serum level of immune complexes (r = 0.46, P less than 0.01) and the number of peripheral lymphocytes inversely (r = -0.49, P less than 0.01). Serum gamma-IFN levels were also higher in patients with SLE than in control subjects but no correlations were found between it and either clinical activity, renal histological activity or various laboratory parameters. Serum levels of both alpha-IFN and gamma-IFN were higher in SLE patients with erythema than in those without. These results suggested that serum levels of alpha-IFN were more closely related to clinical activity of SLE than were those of gamma-IFN, and that peripheral lymphocytes were probably not the source of the elevated serum IFN-alpha concentration.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2449306      PMCID: PMC1542177     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  29 in total

1.  Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.

Authors:  J J Hooks; G W Jordan; T Cupps; H M Moutsopoulos; A S Fauci; A L Notkins
Journal:  Arthritis Rheum       Date:  1982-04

2.  Interferon inhibits the suppressor T cell response of delayed-type hypersensitivity.

Authors:  J Knop; R Stremmer; C Neumann; E De Maeyer; E Macher
Journal:  Nature       Date:  1982-04-22       Impact factor: 49.962

3.  Measurement of interferon from in vitro stimulated lymphocytes by bioassay and monoclonal antibody-based immunoassay.

Authors:  G M Scott; J A Robinson; D S Secher; C M Ashburner; S R Abbott
Journal:  J Gen Virol       Date:  1985-07       Impact factor: 3.891

4.  Human anti-DNA antibody: reference standards for diagnosis and management of systemic lupus erythematosus.

Authors:  J Holian; I D Griffiths; D N Glass; R N Maini; J T Scott
Journal:  Ann Rheum Dis       Date:  1975-10       Impact factor: 19.103

5.  Correlation between clinical activity of systemic lupus erythematosus and the amounts of DNA in DNA/anti-DNA antibody immune complexes.

Authors:  C Morimoto; H Sano; T Abe; M Homma; A D Steinberg
Journal:  J Immunol       Date:  1982-11       Impact factor: 5.422

6.  Spontaneous production of interferon-gamma and acid-labile interferon-alpha by subpopulations of human mononuclear cells.

Authors:  D G Fischer; M Rubinstein
Journal:  Cell Immunol       Date:  1983-10-15       Impact factor: 4.868

7.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

8.  Natural killer cells and interferon responses in patients with systemic lupus erythematosus.

Authors:  G C Tsokos; A H Rook; J Y Djeu; J E Balow
Journal:  Clin Exp Immunol       Date:  1982-11       Impact factor: 4.330

9.  Interferon-gamma induces enhanced expression of Ia and H-2 antigens on B lymphoid, macrophage, and myeloid cell lines.

Authors:  G H Wong; I Clark-Lewis; L McKimm-Breschkin; A W Harris; J W Schrader
Journal:  J Immunol       Date:  1983-08       Impact factor: 5.422

10.  Immune human lymphocytes produce an acid-labile alpha-interferon.

Authors:  F R Balkwill; D B Griffin; H A Band; P C Beverley
Journal:  J Exp Med       Date:  1983-03-01       Impact factor: 14.307

View more
  66 in total

Review 1.  Biomarkers in systemic lupus erythematosus.

Authors:  Gabor G Illei; Peter E Lipsky
Journal:  Curr Rheumatol Rep       Date:  2004-10       Impact factor: 4.592

2.  Structural insights into a human anti-IFN antibody exerting therapeutic potential for systemic lupus erythematosus.

Authors:  Songying Ouyang; Bin Gong; Jin-Zhi Li; Li-Xia Zhao; Wei Wu; Fu-Shun Zhang; Lina Sun; Shu-Jun Wang; Meng Pan; Chuan Li; Wenguang Liang; Neil Shaw; Jie Zheng; Guo-Ping Zhao; Ying Wang; Zhi-Jie Liu; Mifang Liang
Journal:  J Mol Med (Berl)       Date:  2012-02-04       Impact factor: 4.599

3.  Ligation of CD180 inhibits IFN-α signaling in a Lyn-PI3K-BTK-dependent manner in B cells.

Authors:  Ming You; Guanjun Dong; Fanlin Li; Feiya Ma; Jing Ren; Yujun Xu; Huimin Yue; Ruijing Tang; Deshan Ren; Yayi Hou
Journal:  Cell Mol Immunol       Date:  2015-08-17       Impact factor: 11.530

4.  Treatment of neuromyelitis optica: current debate.

Authors:  Tomoko Okamoto; Masafumi Ogawa; Youwei Lin; Miho Murata; Sachiko Miyake; Takashi Yamamura
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

5.  Possible involvement of interferon alfa in the pathogenesis of fever in systemic lupus erythematosus.

Authors:  Y Kanayama; T Kim; H Inariba; N Negoro; M Okamura; T Takeda; T Inoue
Journal:  Ann Rheum Dis       Date:  1989-10       Impact factor: 19.103

6.  Plasmacytoid dendritic cells (natural interferon- alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions.

Authors:  L Farkas; K Beiske; F Lund-Johansen; P Brandtzaeg; F L Jahnsen
Journal:  Am J Pathol       Date:  2001-07       Impact factor: 4.307

Review 7.  Detecting shared pathogenesis from the shared genetics of immune-related diseases.

Authors:  Alexandra Zhernakova; Cleo C van Diemen; Cisca Wijmenga
Journal:  Nat Rev Genet       Date:  2009-01       Impact factor: 53.242

8.  Donor APOL1 high-risk genotypes are associated with increased risk and inferior prognosis of de novo collapsing glomerulopathy in renal allografts.

Authors:  Dominick Santoriello; Syed A Husain; Sacha A De Serres; Andrew S Bomback; Russell J Crew; Elena-Rodica Vasilescu; Geo Serban; Eric S Campenot; Krzysztof Kiryluk; Sumit Mohan; Gregory A Hawkins; Pamela J Hicks; David J Cohen; Jai Radhakrishnan; Michael B Stokes; Glen S Markowitz; Barry I Freedman; Vivette D D'Agati; Ibrahim Batal
Journal:  Kidney Int       Date:  2018-10-02       Impact factor: 10.612

9.  Functional genetic polymorphisms in ILT3 are associated with decreased surface expression on dendritic cells and increased serum cytokines in lupus patients.

Authors:  Mark A Jensen; Karen C Patterson; Akaash A Kumar; Marissa Kumabe; Beverly S Franek; Timothy B Niewold
Journal:  Ann Rheum Dis       Date:  2012-08-17       Impact factor: 19.103

10.  Differential microRNA profile and post-transcriptional regulation exist in systemic lupus erythematosus patients with distinct autoantibody specificities.

Authors:  Sudhir Kumar Chauhan; Vikas Vikram Singh; Richa Rai; Madhukar Rai; Geeta Rai
Journal:  J Clin Immunol       Date:  2014-05       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.